Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Dow
Medtronic
AstraZeneca
Colorcon
Johnson and Johnson
Harvard Business School

Last Updated: January 28, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Mibefradil

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug Mibefradil?

Mibefradil is an investigational drug.

There have been 5 clinical trials for Mibefradil. The most recent clinical trial was a Phase 1 trial, which was initiated on May 28th 2018.

The most common disease conditions in clinical trials are Dilatation, Pathologic, Nervous System Neoplasms, and Glioma. The leading clinical trial sponsors are Cavion LLC, Celerion, and Laboratorios Grossman, S.A.

There are nine hundred and eighty-four US patents protecting this investigational drug and seven international patents.

Recent Clinical Trials for Mibefradil
TitleSponsorPhase
Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican PopulationInstituto Nacional de Salud Publica, MexicoPhase 3
Clinical Trial to Evaluate the Efficacy of a Dyslipidemic Therapy in Mexican PopulationLaboratorios Grossman, S.A.Phase 3
TAU-2014-1: Mibefradil and Hypofractionated Re-Irradiation Therapy in Recurrent GBMYale UniversityPhase 1

See all Mibefradil clinical trials

Clinical Trial Summary for Mibefradil

Top disease conditions for Mibefradil
Top clinical trial sponsors for Mibefradil

See all Mibefradil clinical trials

US Patents for Mibefradil

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Mibefradil   Start Trial Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof The Regents of the University of California (Oakland, CA)   Start Trial
Mibefradil   Start Trial Neprilysin inhibitors THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA)   Start Trial
Mibefradil   Start Trial Synthetic linear apelin mimetics for the treatment of heart failure NOVARTIS AG (Basel, CH)   Start Trial
Mibefradil   Start Trial Ultra-pure agonists of guanylate cyclase C, method of making and using same SYNERGY PHARMACEUTICALS, INC. (New York, NY)   Start Trial
Mibefradil   Start Trial Liquid dosage forms of sodium naproxen Patheon Softgels, Inc. (High Point, NC)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Mibefradil

Drugname Country Document Number Estimated Expiration Related US Patent
Mibefradil European Patent Office 2981556 2033-04-02   Start Trial
Mibefradil World Intellectual Property Organization (WIPO) 2014165513 2033-04-02   Start Trial
Mibefradil Australia 2015210983 2034-01-30   Start Trial
Mibefradil Canada 2934936 2034-01-30   Start Trial
Mibefradil China 105992763 2034-01-30   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Mallinckrodt
McKesson
Dow
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.